In addition, further studies are warranted to evaluate the response of PARP inhibitor in these patients because of the high proportion BRCA2-like genomic rearrangements, although BRCA1/2 mutations are seldom observed in NSCLC patients35. The gene discussed is BRCA1; the disease is non-small cell lung carcinoma.